Zeenat Qureshi Stroke Research Center, Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA.
Neurocrit Care. 2013 Apr;18(2):170-7. doi: 10.1007/s12028-012-9803-0.
Intracerebral hemorrhage (ICH) is an infrequent complication of intravenous recombinant tissue plasminogen activator (rt-PA) for the treatment of acute stroke. However, such ICH is an important reason for withdrawal of care because of lack of adequate data regarding long-term patient outcomes.
To report the long-term outcomes in patients with post-thrombolytic ICH.
We analyzed patient data from a randomized, placebo-controlled trial in patients with ischemic stroke presenting within 3 h of symptom onset. Baseline clinical characteristics and outcomes defined by modified Rankin scale (mRS) were ascertained at 3, 6, and 12 months after treatment in patients who suffered from post-thrombolytic ICH. Favorable outcome was defined by mRS of 0-3 and unfavorable outcome by mRS of 4-6 at 1 year.
A total of 48 patients suffered post-thrombolytic ICH in the trial. Fourteen patients had favorable outcomes and 34 patients had unfavorable outcomes. Clinical characteristics did not have an impact on patient outcomes at 12 months. Patients with unfavorable outcomes were more likely to have an National Institutes of Health Stroke Scale (NIHSS) score ≥ 20 at 7-10 days after treatment (64 vs. 7 %, p < 0.0009). Patients with unfavorable outcomes were more likely to have a worsening of NIHSS score of >4 points at 7-10 days from their baseline NIHSS (44 vs. 0 %, p = 0.0006).
Approximately 30 % of patients with post-thrombolytic ICH have favorable outcomes at 1 year which does not support early withdrawal of care. Ascertainment of NIHSS score and worsening of NIHSS score at 7-10 days may be necessary for accurate prognostic stratification.
静脉注射重组组织型纤溶酶原激活剂(rt-PA)治疗急性脑卒中后,颅内出血(ICH)是一种罕见的并发症。然而,由于缺乏关于长期患者预后的数据,此类 ICH 是停止治疗的一个重要原因。
报告溶栓后 ICH 患者的长期预后。
我们分析了一项针对发病 3 小时内的缺血性脑卒中患者的随机、安慰剂对照试验的患者数据。在治疗后 3、6 和 12 个月,通过改良 Rankin 量表(mRS)评估基线临床特征和预后。1 年时,mRS 评分 0-3 为预后良好,mRS 评分 4-6 为预后不良。
试验中共有 48 例患者发生溶栓后 ICH。14 例患者预后良好,34 例患者预后不良。12 个月时,临床特征对患者预后无影响。预后不良的患者在治疗后 7-10 天 NIHSS 评分≥20 的可能性更大(64%比 7%,p<0.0009)。预后不良的患者在治疗后 7-10 天 NIHSS 评分较基线增加>4 分的可能性更大(44%比 0%,p=0.0006)。
大约 30%的溶栓后 ICH 患者在 1 年后预后良好,这并不支持早期停止治疗。在 7-10 天评估 NIHSS 评分和 NIHSS 评分的变化可能对准确的预后分层是必要的。